학술논문

Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.
Document Type
Article
Source
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p382-382, 140p
Subject
Language
ISSN
0732183X